vertex pharmaceuticals

Between the July 31 and August 14 settlement dates, the number of shares short in the leading biotech and emerging pharmaceutical stocks was mixed. Short sellers were especially drawn to Biogen Inc (NASDAQ: BIIB), Gilead Sciences, Inc. (NASDAQ: GILD) and Vertex Pharmaceuticals Incorporated (...

While short interest in most of the leading biotechs and emerging pharmaceuticals shrank between the March 31 and April 15 settlement dates, three stocks bucked that trend. Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) saw the number of their shares...

Short interest among leading biotechs and emerging pharmaceuticals increased nearly all across the board between February 13 and February 27. Leading the trend were BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ:...

By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals...

By and large, short interest among the leading biotechs and emerging pharmaceuticals dwindled between the January 15 and January 30 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Here...

Biotechs continue to prove volatile this year. While Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN) saw a sizable drops in short interest between the September 15 and September 30 settlement dates, short sellers loaded up on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX...

U.S. stocks declined as the recent round of violence in Iraq may have escalated following reports that Syrian warplanes conducted raids in western Iraq, killing at least 50 people. The CBOE Volatility Index, also referred to as the "fear index", rose more than ten percent, trading...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Among the leading biotech and emerging pharmaceutical companies, Incyte (NASDAQ: INCY) and Pharmacyclics (NASDAQ: PCYC) saw the largest percentage declines in short interest between the January 15 and January 31 settlement dates. Short sellers shied away from Alexion Pharmaceuticals, Amgen, Biogen...

Among the leading biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) saw the most significant upswings between the December 31 and January 15 settlement dates. Gilead Sciences, Pharmacyclics and Regeneron...